Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04053283 · ClinicalTrials.gov registry record · Phase 1
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
A Phase 1 study, sponsored by Akamis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 186
- Enrollment target
NCT04053283 is a Phase 1 study that has completed, run by Akamis Bio. The registered enrollment target is 186 participants.
The verdict
NCT04053283, a Phase 1 study, has completed, sponsored by Akamis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 186 participants
- Enrollment target
Study Summary
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
Interventions
- BIOLOGICAL NG-641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04053283
The ClinicalTrials.gov registry entry for NCT04053283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akamis Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NG-641 is the first listed.
NCT04053283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04053283 about?
NCT04053283 is a clinical study titled "First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector". To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
What is the current status of trial NCT04053283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2020-01-23. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT04053283?
The interventions under investigation include: NG-641 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04053283?
This trial is sponsored by Akamis Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.